Jeff Sharman

Jeff Sharman M.D. is the medical director of hematology research for the US Oncology / Sarah Cannon Research Institute network. This consortium manages approximately one out of every five cancer patients treated in the United States and is the largest private research network in the country. 

Dr Sharman developed the original idea of using BTK inhibitors to treat lymphoid malignancies and conducted the first in human studies of ibrutinib within his private practice at the Willamette Valley Cancer and Research Center in Eugene, Oregon, US. He has led phase 3 studies of acalabrutinib and pirtobrutinib leading to their regulatory approval among many other therapies in the management of lymphoma and leukemia. He knows that the heart is somewhere in the chest between the lungs and has some important jobs and was proud to go to residency at Massachusetts General Hospital with a total of 8 co-residents who specialised in electrophysiology – so most of what he knows in cardiology was by osmosis from his peers.